Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$1.20
-1.6%
$0.97
$0.70
$1.61
$68.25M1.05148,110 shs75,233 shs
InspireMD, Inc. stock logo
NSPR
InspireMD
$2.41
-1.6%
$2.50
$2.07
$3.80
$73.83M0.5939,498 shs18,371 shs
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
$1.12
-5.9%
$1.42
$0.59
$4.49
$19.75M41.19 million shs52,042 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$4.82
$4.67
$4.01
$9.33
$79.10M1.32194,043 shs62,515 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-1.64%+13.21%+33.33%+6.19%+44.21%
InspireMD, Inc. stock logo
NSPR
InspireMD
-1.63%-1.23%+2.12%-13.93%-3.21%
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-5.88%-10.76%-11.81%-54.29%+48.36%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
0.00%-6.04%+8.07%+0.84%-7.66%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytosorbents Co. stock logo
CTSO
Cytosorbents
1.7577 of 5 stars
3.52.00.00.02.00.00.6
InspireMD, Inc. stock logo
NSPR
InspireMD
2.4891 of 5 stars
3.52.00.00.02.12.50.6
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
2.5116 of 5 stars
3.53.00.00.03.31.70.0
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.5373 of 5 stars
3.62.00.00.03.10.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
3.00
Buy$5.50358.33% Upside
InspireMD, Inc. stock logo
NSPR
InspireMD
3.00
Buy$4.5086.72% Upside
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
3.00
Buy$5.00346.43% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.25
Buy$11.67142.05% Upside

Current Analyst Ratings Breakdown

Latest NXL, SRTS, CTSO, and NSPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $10.00
5/15/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/15/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00
5/12/2025
InspireMD, Inc. stock logo
NSPR
InspireMD
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00
5/2/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/4/2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
4/3/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00
4/1/2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/24/2025
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$5.00
(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
$35.60M2.11N/AN/A$0.20 per share6.00
InspireMD, Inc. stock logo
NSPR
InspireMD
$7.03M10.51N/AN/A$1.83 per share1.32
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
$170K113.19N/AN/A$0.28 per share4.00
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$41.81M1.90$0.43 per share11.14$3.41 per share1.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$20.72M-$0.28N/AN/AN/A-41.77%-105.04%-29.18%8/12/2025 (Estimated)
InspireMD, Inc. stock logo
NSPR
InspireMD
-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-$7.61M-$0.83N/AN/A-6,529.77%-277.92%-245.37%N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$6.65M$0.1048.2020.96N/A4.56%3.34%3.00%8/6/2025 (Estimated)

Latest NXL, SRTS, CTSO, and NSPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.04-$0.16-$0.20-$0.16$7.23 million$8.34 million
5/14/2025Q1 2025
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.08-$0.06+$0.02-$0.02$9.01 million$8.73 million
5/13/2025Q1 2025
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million
3/31/2025Q4 2024
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
-$0.07-$0.03+$0.04-$0.14$10.09 million$9.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
N/AN/AN/AN/AN/A
InspireMD, Inc. stock logo
NSPR
InspireMD
N/AN/AN/AN/AN/A
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytosorbents Co. stock logo
CTSO
Cytosorbents
1.06
1.97
1.58
InspireMD, Inc. stock logo
NSPR
InspireMD
N/A
6.39
6.05
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
N/A
16.42
15.89
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
10.52
7.89

Institutional Ownership

CompanyInstitutional Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
32.87%
InspireMD, Inc. stock logo
NSPR
InspireMD
44.78%
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
0.65%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%

Insider Ownership

CompanyInsider Ownership
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
6.60%
InspireMD, Inc. stock logo
NSPR
InspireMD
34.06%
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
24.00%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cytosorbents Corporation stock logo
CTSO
Cytosorbents
22062.61 million58.48 millionOptionable
InspireMD, Inc. stock logo
NSPR
InspireMD
5030.64 million18.33 millionOptionable
Nexalin Technology, Inc. stock logo
NXL
Nexalin Technology
317.18 million13.06 millionNot Optionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
4016.44 million14.98 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cytosorbents stock logo

Cytosorbents NASDAQ:CTSO

$1.20 -0.02 (-1.64%)
Closing price 06/17/2025 04:00 PM Eastern
Extended Trading
$1.21 +0.01 (+0.83%)
As of 06/17/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

InspireMD stock logo

InspireMD NYSE:NSPR

$2.41 -0.04 (-1.63%)
Closing price 06/17/2025 04:00 PM Eastern
Extended Trading
$2.59 +0.18 (+7.47%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Nexalin Technology stock logo

Nexalin Technology NASDAQ:NXL

$1.12 -0.07 (-5.88%)
Closing price 06/17/2025 04:00 PM Eastern
Extended Trading
$1.13 +0.01 (+0.89%)
As of 06/17/2025 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

Sensus Healthcare stock logo

Sensus Healthcare NASDAQ:SRTS

$4.82 0.00 (0.00%)
Closing price 06/17/2025 04:00 PM Eastern
Extended Trading
$4.90 +0.08 (+1.66%)
As of 07:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.